LEAP 2026 opens with health tech on the fringe of an AI show
LEAP opened its fifth edition in Riyadh this morning, and life sciences readers should set expectations accordingly. This is an artificial intelligence and infrastructure event that carries a HealthTech track, not a health event. As the doors opened at the Riyadh Exhibition and Convention Centre in Malham, no biotech, pharmaceutical or digital health announcement had been tied to the show.
That is worth stating plainly, because the volume of coverage around LEAP tends to imply that everything is happening everywhere. It is not. The Kingdom's technology spending has been overwhelmingly directed at compute, cloud and connectivity, and the life sciences story in Saudi Arabia remains some distance behind. The compute is arriving in Riyadh well ahead of the science that might use it.
What is actually on the programme
Two device demonstrations carry most of the clinical interest, and both sit in the Tech Arena rather than in any deal flow.
PSYONIC is presenting its AI-powered prosthetic hand, with founder and chief executive Aadeel Akhtar speaking. The device reads muscle signals to drive articulation, and it belongs to a class of myoelectric prostheses that has moved from research curiosity to commercial product over the past decade.
Cognixion is showing Axon-R, a non-invasive brain-computer interface that combines electroencephalography, augmented reality and machine learning, presented by founder Andreas Forsland. Non-invasive BCI has an obvious ceiling relative to implanted systems, but the assistive communication use case is real and the regulatory path is considerably shorter.
Organisers say 93 per cent of Tech Arena sessions will include a live demonstration, working prototype or inventor-led conversation, up from 62 per cent in 2025. That is an organiser figure and, like the rest of them this week, unverified.
Beyond those two, healthcare appears as an application area within the DeepFest programme, which runs co-located and is powered by SDAIA, and as a conference track in the main agenda. There is no dedicated life sciences pavilion, no named pharmaceutical participant, and no announced clinical or research partnership.
The case for paying attention anyway
The argument for watching Riyadh is not what is being announced in health this week. It is what the infrastructure implies for the next three to five years.
HUMAIN, the state-owned AI company launched in May 2025, has broken ground on twin 100 MW campuses in Riyadh and Dammam and holds land with access to 14 gigawatts of power, against a stated target of 1.9 gigawatts of built capacity by 2030. Sovereign-scale compute of that kind has, elsewhere, preceded serious investment in structural biology, molecular simulation and clinical data platforms. Whether Saudi Arabia follows that path or simply rents the capacity out is an open question, and nothing this week answers it.
The workforce picture is more concrete. Communications and information technology minister Abdullah Al-Swaha said ahead of the opening that around 30,000 people have been trained in artificial intelligence and that more than 80 technical schools are operating. He also put the digital economy at around SAR 522bn, roughly $139bn, up more than 75 per cent since Vision 2030 began, with 410,000 jobs in the sector. None of that is health-specific, but a bioinformatics capability has to be built on exactly that base.
Where a health story might come from
Three places, on this week's evidence.
The first is the investor floor. LEAP said today that 1,289 investors from 1,016 firms are registered, representing $14.5tn in combined assets under management. That figure is organiser-supplied and sits awkwardly beside a separate government release quoting 1,900 investors, so treat it as an indication of scale rather than a count. Among named attendees are the Public Investment Fund, Sanabil Investments, General Atlantic, J.P. Morgan and Morgan Stanley. Life sciences allocators are not obviously among them.
The second is Rocket Fuel, the startup competition, which has 100 finalists drawn from more than 3,000 applications competing for a $1m equity-free prize pool across 12 sectors and more than 60 subsectors. The grand finale is on 3 September. Whether any health or biotech company reaches the final is one of the few genuinely open questions of the week.
The third is the ministerial trail. Large projects involving Amazon and Nvidia were signalled for today, with no values or structures disclosed. If any carries a health or genomics component, it will be the first substantive life sciences item of the show.
Until then, this is a compute story with a health track attached, and it should be read that way.